

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

	Application Number	10/603,889	
	Filing Date	June 25, 2003	
	First Named Inventor	Hossainy	
	Art Unit	1762	
	Examiner Name	B. P. Chen	
Total Number of Pages in This Submission (excluding references)	18	Attorney Docket Number	50623.257

**ENCLOSURES (check all that apply)**

<input checked="" type="checkbox"/> Fee Transmittal Form (in duplicate)  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Response To Office Action  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input checked="" type="checkbox"/> Information Disclosure Statement (2 pages) (in duplicate) with Form PTO-1449 (12 pgs) citing 337 Reference  <input type="checkbox"/> Express Mail Label No.  <input checked="" type="checkbox"/> Postage Paid Return Postcard  <input checked="" type="checkbox"/> Deposit Account 07-1850 Authorization  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Amendment Transmittal letter  <input type="checkbox"/> Response To Restriction Requirement  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Statement of Common Ownership  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  65 References
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Charles E. Ruyyan, Jr., Ph.D. Reg. No. 43,096
Signature	
Date	April 11, 2005

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as Express Mail in a box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Vera Breder		
Signature		Date	April 13, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

#149004



# FEE TRANSMITTAL for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

## Complete if Known

Application Number 10/603,889  
Filing Date June 25, 2003  
First Named Inventor Hossainy  
Examiner Name B. P. Chen  
Art Unit 1762  
Attorney Docket No. 50623.257

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money ☐ Other ☐ None  
Order

☒ Deposit Account:

Deposit  
Account  
Number 07-1850

Deposit  
Account  
Name Squire, Sanders & Dempsey L.L.P.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)  
☐ Charge fee(s) indicated below, except for the filing fee  
to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	300	2001	150	Utility filing fee	
1002	200	2002	100	Design filing fee	
1003	200	2003	100	Plant filing fee	
1004	300	2004	150	Reissue filing fee	
1005	200	2005	100	Provisional filing fee	
SUBTOTAL (1)					(\$)

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total Claims	-32 **	=	X 0	=
Independent Claims	-3 **	=	X	=
Multiple Dependent			X	= 0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	50	2202	25	Claims in excess of 20
1201	200	2201	100	Independent claims in excess of 3
1203	360	2203	180	Multiple dependent claim, if not paid
1204	200	2204	100	** Reissue independent claims over original patent
1205	50	2205	25	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)				

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	
1401	340	2401	170	Notice of Appeal	
1402	340	2402	170	Filing a brief in support of an appeal	
1403	300	2403	150	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,370	2453	685	Petition to revive - unintentional	
1501	1,370	2501	685	Utility issue fee (or reissue)	
1502	490	2502	245	Design issue fee	
1503	660	2503	330	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1814	130	2814	65	Terminal Disclaimer	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

## SUBMITTED BY

## Complete (if applicable)

Name (Print/Type) Charles B. Runyan, Jr., PhD Registration No. (Attorney/Agent) 43,066 Telephone (415) 954-0200  
Signature *Charles B. Runyan* Date April 11 2005

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Examiner: B. P. Chen

Hossainy et al.

Serial No.: 10/603,889

Art Unit: 1762

Filed: June 25, 2003

Title: FLUID TREATMENT OF A POLYMERIC COATING ON AN  
IMPLANTABLE MEDICAL DEVICE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove the listed documents as a competent reference against the claims of the present application. The submission of this Supplemental Information Disclosure Statement is not to be

construed as a representation that a search has been made or that no other material information may exist.


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Supplemental Information Disclosure Statement is being submitted after receiving an Office Action and after three months of the filing date of the above-identified application. Therefore, please charge Deposit Account No. **07-1850** in the amount of **\$180.00** as specified in 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p).

Date: April 11 2005

SQUIRE, SANDERS & DEMPSEY L.L.P.  
One Maritime Plaza, Suite 300  
San Francisco, CA 94111  
Telephone (415) 954-0200  
Facsimile (415) 393-9887

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Charles E. Runyan", written over a horizontal line.

Charles E. Runyan, Ph.D.  
Attorney for Applicants  
Reg. No. 43,066

<b>FORM PTO-1449 (Modified)</b>		<b>US DEPARTMENT OF COMMERCE</b>		Docket No. <b>50623.257</b>		Application No. <b>10/603,889</b>	
US Patent and Trademark Office				Applicant <b>Hossainy</b>			
<b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)				Filing Date <b>June 25, 2003</b>		Group Art Unit <b>1762</b>	

U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	3,687,135	8/29/72	Stroganov et al.			
	A2	3,839,743	10/8/74	Schwarcz			
	A3	3,900,632	8/19/75	Robinson			
	A4	4,104,410	8/1/78	Malecki			
	A5	4,110,497	8/29/78	Hoel			
	A6	4,321,711	3/30/82	Mano			
	A7	4,346,028	8/24/82	Griffith			
	A8	4,596,574	6/24/86	Urist			
	A9	4,599,085	7/8/86	Riess et al.			
	A10	4,612,009	9/16/86	Drobnik et al.			
	A11	4,633,873	1/6/87	Dumican et al.			
	A12	4,656,083	4/7/87	Hoffman et al.			
	A13	4,718,907	1/12/88	Karwoski et al.			
	A14	4,722,335	2/2/88	Vilasi			
	A15	4,723,549	2/9/88	Wholey et al.			
	A16	4,732,152	3/22/88	Wallstén et al.			
	A17	4,739,762	4/26/88	Palmaz			
	A18	4,740,207	4/26/88	Kreamer			
	A19	4,743,252	5/10/88	Martin, Jr. et al.			
	A20	4,768,507	9/6/88	Fischell et al.			
	A21	4,776,337	10/11/88	Palmaz			
	A22	4,816,339	3/28/89	Tu et al.			
	A23	4,818,559	4/4/89	Hama et al.			
	A24	4,850,999	7/25/89	Planck			
	A25	4,877,030	10/31/89	Beck et al.			
	A26	4,878,906	11/7/89	Lindemann et al.			
	A27	4,879,135	11/7/89	Greco et al.			

	A28	4,902,289	2/20/90	Yannas			
	A29	4,994,298	2/19/91	Yasuda			
	A30	5,019,090	5/28/91	Pinchuk			
	A31	5,028,597	7/2/91	Kodama et al.			
	A32	5,059,211	10/22/91	Stack et al.			
	A33	5,062,829	11/5/91	Pryor et al.			
	A34	5,084,065	1/28/92	Weldon et al.			
	A35	5,085,629	2/4/92	Goldberg et al.			
	A36	5,100,429	3/31/92	Sinofsky et al.			
	A37	5,104,410	4/14/92	Chowdhary			
	A38	5,108,755	4/28/92	Daniels et al.			
	A39	5,108,417	4/28/92	Sawyer			
	A40	5,123,917	6/23/92	Lee			
	A41	5,156,623	10/20/92	Hakamatsuka et al.			
	A42	5,163,951	11/17/92	Pinchuk et al.			
	A43	5,163,958	11/17/92	Pinchuk			
	A44	5,163,952	11/17/92	Froix			
	A45	5,167,614	12/1/92	Tessmann et al.			
	A46	5,192,311	3/9/93	King et al.			
	A47	5,197,977	3/30/93	Hoffman, Jr. et al.			
	A48	5,234,456	8/10/93	Silvestrini			
	A49	5,234,457	8/10/93	Andersen			
	A50	5,236,447	8/17/93	Kubo et al.			
	A51	5,279,594	1/18/94	Jackson			
	A52	5,282,860	2/1/94	Matsuno et al.			
	A53	5,289,831	3/1/94	Bosley			
	A54	5,290,271	3/1/94	Jernberg			
	A55	5,306,286	4/26/94	Stack et al.			
	A56	5,306,294	4/26/94	Winston et al.			
	A57	5,330,500	7/19/94	Song			
	A58	5,342,348	8/30/94	Kaplan			
	A59	5,342,395	8/30/94	Jarrett et al.			
	A60	5,342,621	8/30/94	Eury			

A61	5,356,433	10/18/94	Rowland et al.			
A62	5,383,925	1/24/95	Schmitt			
A63	5,385,580	1/31/95	Schmitt			
A64	5,389,106	2/14/95	Tower			
A65	5,399,666	3/21/95	Ford			
A66	5,423,885	6/13/95	Williams			
A67	5,441,515	8/15/95	Khosravi et al.			
A68	5,443,458	8/22/95	Eury et al.			
A69	5,443,500	8/22/95	Sigwart			
A70	5,455,040	10/3/95	Marchant			
A71	5,502,158	3/26/96	Sinclair et al.			
A72	5,514,379	5/7/96	Weissleder et al.			
A73	5,527,337	6/18/96	Stack et al.			
A74	5,545,408	8/13/96	Trigg et al.			
A75	5,554,120	9/10/96	Chen et al.			
A76	5,556,413	9/17/96	Lam			
A77	5,578,046	11/26/96	Liu et al.			
A78	5,591,607	1/7/97	Gryaznov et al.			
A79	5,591,199	1/7/97	Porter et al.			
A80	5,593,403	1/14/97	Buscemi			
A81	5,593,434	1/14/97	Williams			
A82	5,599,301	2/4/97	Jacobs et al.			
A83	5,599,922	2/4/97	Gryaznov et al.			
A84	5,607,442	3/4/97	Fischell et al.			
A85	5,607,467	3/4/97	Froix			
A86	5,618,299	4/8/97	Khosravi et al.			
A87	5,629,077	5/13/97	Turnlund et al.			
A88	5,629,077	5/13/97	Turnlund et al.			
A89	5,631,135	5/20/97	Gryaznov et al.			
A90	5,632,771	5/27/97	Boatman et al.			
A91	5,632,840	5/27/97	Campbell			
A92	5,637,113	6/10/97	Tartaglia et al.			
A93	5,667,796	9/16/97	Otten			

	A94	5,693,085	12/2/97	Buirge et al.			
	A95	5,707,385	1/13/98	Williams			
	A96	5,711,763	1/27/98	Nonami et al.			
	A97	5,725,549	3/10/98	Lam			
	A98	5,726,297	3/10/98	Gryaznov et al.			
	A99	5,728,751	3/17/98	Patnaik			
	A100	5,733,925	3/31/98	Kunz et al.			
	A101	5,733,326	3/31/98	Tomonto et al.			
	A102	5,733,330	3/31/98	Cox			
	A103	5,733,564	3/31/98	Lehtinen			
	A104	5,741,881	4/21/98	Patnaik			
	A105	5,756,457	5/26/98	Wang et al.			
	A106	5,756,476	5/26/98	Epstein et al.			
	A107	5,766,710	6/16/98	Turnlund et al.			
	A108	5,765,682	6/16/98	Bley et al.			
	A109	5,766,204	6/16/98	Porter et al.			
	A110	5,766,239	6/16/98	Cox			
	A111	5,766,710	6/16/98	Turnlund et al.			
	A112	5,769,883	6/23/98	Buscemi et al.			
	A113	5,780,807	7/14/98	Saunders			
	A114	5,800,516	9/1/98	Fine et al.			
	A115	5,811,447	9/22/98	Kunz et al.			
	A116	5,830,461	11/3/98	Billiar			
	A117	5,830,879	11/3/98	Isner			
	A118	5,833,651	11/10/98	Donovan et al.			
	A119	5,834,582	11/10/98	Sinclair et al.			
	A120	5,837,835	11/17/98	Gryaznov et al.			
	A121	5,836,962	11/17/98	Gianotti			
	A122	5,840,083	11/24/98	Braach-Maksvytis			
	A123	5,854,207	12/29/98	Lee et al.			
	A124	5,853,408	12/29/98	Muni			
	A125	5,855,612	1/5/99	Ohthuki et al.			
	A126	5,855,618	1/5/99	Patnaik et al.			



	A127	5,868,781	2/9/99	Killion			
	A128	5,874,165	2/23/99	Drumheller			
	A129	5,874,101	2/23/99	Zhong et al.			
	A130	5,874,109	2/23/99	Ducheyne et al.			
	A131	5,876,743	3/2/99	Ibsen et al.			
	A132	5,877,263	3/2/99	Patnaik et al.			
	A133	5,879,713	3/9/99	Roth et al.			
	A134	5,888,533	3/30/99	Dunn			
	A135	5,891,192	4/6/99	Murayama et al.			
	A136	5,897,955	4/27/99	Drumheller			
	A137	5,906,759	5/25/99	Richter			
	A138	5,914,182	6/22/99	Drumheller			
	A139	5,916,870	6/29/99	Lee et al.			
	A140	5,922,005	7/13/99	Richter et al.			
	A141	5,942,209	8/24/99	Leavitt et al.			
	A142	5,948,428	9/7/99	Lee et al.			
	A143	5,954,744	9/21/99	Phan et al.			
	A144	5,957,975	9/28/99	Lafont et al.			
	A145	5,965,720	10/12/99	Gryaznov et al.			
	A146	5,976,182	11/2/99	Cox			
	A147	5,980,564	11/9/99	Stinson			
	A148	5,981,568	11/9/99	Kunz et al.			
	A149	5,986,169	11/16/99	Gjunter			
	A150	5,997,468	12/7/99	Wolff et al.			
	A151	6,010,445	1/4/00	Armini et al.			
	A152	6,048,964	4/11/00	Lee et al.			
	A153	6,066,156	5/23/00	Yan			
	A154	6,071,266	6/6/00	Kelley			
	A155	6,074,659	6/13/00	Kunz et al.			
	A156	6,080,177	6/27/00	Igaki et al.			
	A157	6,083,258	7/4/00	Yadav			
	A158	6,093,463	7/25/00	Thakrar			
	A159	6,096,525	8/1/00	Patnaik			

	A160	6,103,230	8/15/00	Billiar et al.			
	A161	6,107,416	8/22/00	Patnaik et al.			
	A162	6,117,979	9/12/00	Hendriks et al.			
	A163	6,125,523	10/3/00	Brown et al.			
	A164	6,127,173	10/3/00	Eckstein et al.			
	A165	6,129,928	10/10/00	Sarangapani et al.			
	A166	6,150,630	11/21/00	Perry et al.			
	A167	B1 4,776,337	12/5/00	Palmas (Reexamination Certificate)			
	A168	6,159,951	12/12/00	Karpeisky et al.			
	A169	6,160,084	12/12/00	Langer et al.			
	A170	6,166,130	12/26/00	Rhee et al.			
	A171	6,169,170	1/2/01	Gryaznov et al.			
	A172	6,171,609	1/9/01	Kunz			
	A173	6,174,330	1/16/01	Stinson			
	A174	6,177,523	1/23/01	Reich et al.			
	A175	6,183,505	2/6/01	Mohn, Jr. et al.			
	A176	6,187,045	2/13/01	Fehring et al.			
	A177	6,210,715	4/3/01	Starling et al.			
	A178	6,224,626	5/1/01	Steinke			
	A179	6,228,845	5/8/01	Donovan et al.			
	A180	6,245,076	6/12/01	Yan			
	A181	6,245,103	6/12/01	Stinson			
	A182	6,248,344	6/19/01	Ylanen et al.			
	A183	6,251,135	6/26/01	Stinson et al.			
	A184	6,251,142	6/26/01	Bernacca et al.			
	A185	6,273,913	8/14/01	Wright et al.			
	A186	6,281,262	8/28/01	Shikinami			
	A187	6,284,333	9/4/01	Wang et al.			
	A188	6,287,332	9/11/01	Bolz et al.			
	A189	6,290,721	9/18/01	Heath			
	A190	6,293,966	9/25/01	Frantzen			
	A191	6,303,901	10/16/01	Perry et al.			
	A192	6,312,459	11/6/01	Huang et al.			

	A193	6,327,772	12/11/01	Zadno-Azizi et al.			
	A194	4,733,665 C2	1/29/02	Palmaz (Reexamination Certificate)			
	A195	6,375,826	4/23/02	Wang et al.			
	A196	6,387,121	5/14/02	Alt			
	A197	6,388,043	5/14/02	Langer et al.			
	A198	6,409,761	6/25/02	Jang			
	A199	6,423,092	7/23/02	Datta et al.			
	A200	6,461,632	10/8/02	Gogolewski			
	A201	6,464,720	10/15/02	Boatman et al.			
	A202	6,479,565	11/12/02	Stanley			
	A203	6,485,512	11/26/02	Cheng			
	A204	6,492,615	12/10/02	Flanagan			
	A205	6,494,908	12/17/02	Huxel et al.			
	A206	6,495,156	12/17/02	Wenz et al.			
	A207	6,511,748	1/28/03	Barrows			
	A208	6,517,888	2/11/03	Weber			
	A209	6,537,589	3/25/03	Chae et al.			
	A210	6,539,607	4/1/03	Fehring et al.			
	A211	6,540,777	4/1/03	Stenzel			
	A212	6,554,854	4/29/03	Flanagan			
	A213	6,565,599	5/20/03	Hong et al.			
	A214	6,569,191	5/27/03	Hogan			
	A215	6,569,193	5/27/03	Cox et al.			
	A216	6,572,672	6/3/03	Yadav et al.			
	A217	6,574,851	6/10/03	Mirizzi			
	A218	6,585,755	7/1/03	Jackson et al.			
	A219	6,592,614	7/15/03	Lenker et al.			
	A220	6,592,617	7/15/03	Thompson			
	A221	6,613,072	9/2/03	Lau et al.			
	A222	6,626,939	9/30/03	Burnside et al.			
	A223	6,635,269	10/21/03	Jennissen			
	A224	6,645,243	11/11/03	Vallana et al.			
	A225	6,656,162	12/2/03	Santini, Jr. et al.			

	A226	6,664,335	12/16/03	Krishnan			
	A227	6,666,214	12/23/03	Canham			
	A228	6,667,049	12/23/03	Janas et al.			
	A229	6,669,723	12/30/03	Killion et al.			
	A230	6,676,697	1/13/04	Richter			
	A231	6,679,980	1/20/04	Andreacchi			
	A232	6,689,375	2/10/04	Wahlig et al.			
	A233	6,695,920	2/24/04	Pacetti et al.			
	A234	6,706,273	3/16/04	Roessler			
	A235	6,709,379	3/23/04	Brandau et al.			
	A236	6,719,934	4/13/04	Stinson			
	A237	6,719,989	4/13/04	Matsushima et al.			
	A238	6,720,402	4/13/04	Langer et al.			
	A239	6,746,773	6/8/04	Llanos et al.			
	A240	6,752,826	6/22/04	Holloway et al.			
	A241	6,753,007	6/22/04	Haggard et al.			
	A242	6,764,505	7/20/04	Hossainy et al.			
	A243	6,818,063	11/16/04	Kerrigan			
	A244	6,846,323	1/25/05	Yip et al.			
	A245	10/317,435		Hossainy et al.			12/11/02

### U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A246	2001/0044652	11/22/01	Moore			
	A247	2002/0002399	1/3/02	Huxel et al.			
	A248	2002/0004060	1/10/02	Heublein et al.			
	A249	2002/0004101	1/10/02	Ding et al.			
	A250	2002/0062148	5/23/02	Hart			
	A251	2002/0065553	5/30/02	Weber			
	A252	2002/0111590	8/15/02	Davila et al.			
	A253	2002/0116050	8/22/02	Kocur			
	A254	2002/0138133	9/26/02	Lenz et al.			
	A255	2002/0161114	10/31/02	Gunatillake et al.			
	A256	2003/0033001	2/13/03	Igaki			

	A257	2003/0093107	5/15/03	Parsonage et al.			
	A258	2003/0100865	5/29/03	Santini, Jr. et al.			
	A259	2003/0105518	6/5/03	Dutta			
	A260	2003/0105530	6/5/03	Pirhonen			
	A261	2003/0171053	9/11/03	Sanders			
	A262	2003/0187495	10/2/03	Cully et al.			
	A263	2003/0208259	11/6/03	Penhasi			
	A264	2003/0209835	11/13/03	Chun et al.			
	A265	2003/0226833	12/11/03	Shapovalov et al.			
	A266	2003/0236565	12/25/03	Fifer			
	A267	2004/0093077	5/13/04	White et al.			
	A268	2004/0098095	5/20/04	Burnside et al.			
	A269	2004/0111149	6/10/04	Stinson			
	A270	2004/0127970	7/1/04	Weber			
	A271	2004/0143317	7/22/04	Stinson et al.			
	A272	2004/0167610	8/26/04	Fleming III			

### FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	GB 2 247 696	3/11/92	Great Britain				
	B2	DE 44 07 079	9/29/94	German (English Abstract)				
	B3	DE 197 31 021	1/21/99	German (English Abstract)				
	B4	DE 198 56 983	12/30/99	German (English Abstract)				
	B5	EP 0 108 171	5/16/84	EPO				
	B6	EP 0 144 534	6/19/85	EPO				
	B7	EP 0 364 787	4/25/90	EPO				
	B8	EP 0 397 500	11/14/90	EPO				
	B9	EP 0 464 755	1/8/92	EPO				
	B10	EP 0 493 788	7/8/92	EPO				
	B11	EP 0 554 082	8/4/93	EPO				
	B12	EP 0 578 998	1/19/94	EPO (English Abstract)				
	B13	EP 0 621 017	10/26/94	EPO				
	B14	EP 0 709 068	5/1/96	EPO				
	B15	EP 0 970 711	1/12/00	EPO				

	B16	WO 89/03232	4/20/89	PCT				
	B17	WO 90/01969	3/8/90	PCT				
	B18	WO 90/04982	5/17/90	PCT				
	B19	WO 90/06094	6/14/90	PCT				
	B20	WO 91/17744	11/28/91	PCT				
	B21	WO 91/17789	11/28/91	PCT				
	B22	WO 92/10218	6/25/92	PCT				
	B23	WO 93/06792	4/15/93	PCT				
	B24	WO 94/21196	9/29/94	PCT				
	B25	WO 95/29647	11/9/95	PCT				
	B26	WO 98/04415	2/5/98	PCT				
	B27	WO 99/03515	1/28/99	PCT				
	B28	WO 99/16386	4/8/99	PCT				
	B29	WO 99/42147	8/26/99	PCT				
	B30	WO 2004/023985	3/25/04	PCT				
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)								
	C1	Anonymous, <i>Bioabsorbable stent mounted on a catheter having optical coherence tomography capabilities</i> , Research Disclosure, September 2004, pp. 1159-1162.						
	C2	Ansari, <i>Tubal Reanastomosis Using Absorbable Stent</i> , International Journal of Fertility, Vol. 23, No. 4, pp. 242-243 (1978).						
	C3	Ansari, <i>End-to-end tubal anastomosis using an absorbable stent</i> , Fertility and Sterility, Vol. 32(2), pp. 197-201 (August 1979).						
	C4	Bull, <i>Parylene Coating for Medical Applications</i> , Medical Product Manufacturing News 1 pg. (March 1993).						
	C5	Casper et al., <i>Fiber-Reinforced Absorbable Composite for Orthopedic Surgery</i> , Polymeric Materials Science and Engineering, 53: pp. 497-501 (1985).						
	C6	Detweiler et al., <i>Sutureless Anastomosis of the Small Intestine and the Colon in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue</i> , Journal of Investigative Surgery, Vol. 8(2), pp. 129-140 (March 1995).						
	C7	Detweiler et al., <i>Sutureless Cholecystojejunostomy in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue</i> , Journal of Investigative Surgery, Vol. 9(1), pp. 13-26 (Jan./Feb. 1996).						
	C8	Detweiler et al., <i>Sliding, Absorbable, Reinforced Ring and an Axially Driven Stent Placement Device for Sutureless Fibrin Glue Gastrointestinal Anastomosis</i> , Journal of Investigative Surgery, Vol. 9(6), pp. 495-504 (Nov./Dec. 1996).						
	C9	Detweiler et al., <i>Gastrointestinal Sutureless Anastomosis Using Fibrin Glue: Reinforcement of the Sliding Absorbable Intraluminal Nontoxic Stent and Development of a Stent Placement Device</i> , Journal of Investigative Surgery, Vol. 9(2), pp. 111-130 (Mar. /Apr. 1996).						
	C10	Devanathan et al., <i>Polymeric Conformal Coatings for Implantable Electronic Devices</i> , IEEE Transactions on Biomedical Engineering, Vol. BME-27(11), pp. 671-675 (1980).						
	C11	Elbert et al., <i>Conjugate Addition Reactions Combined with Free-Radical Cross-Linking for the Design of Materials for Tissue Engineering</i> , Biomacromolecules 2, pp. 430-441 (2001).						

C12	Feng-Chun et al., <i>Assessment of Tissue Blood Flow Following Small Artery Welding with an Intraluminal Dissolvable Stent</i> , Microsurgery, Vol. 19(3), pp. 148-152 (1999).
C13	Hahn et al., <i>Glow Discharge Polymers as Coatings for Implanted Devices</i> , ISA, pp. 109-111 (1981).
C14	Hahn et al., <i>Biocompatibility of Glow-Discharge-Polymerized Films and Vacuum-Deposited Parylene</i> , J Applied Polymer Sci, 38, pp. 55-64 (1984).
C15	Kelley et al., <i>Totally Resorbable High-Strength Composite Material</i> , Advances in Biomedical Polymers, 35, pp. 75-85 (1987).
C16	Kubies et al., <i>Microdomain Structure In polylactide-block-poly(ethylene oxide) copolymer films</i> , Biomaterials 21, pp. 529-536 (2000).
C17	Kutryk et al., <i>Coronary Stenting: Current Perspectives</i> , a companion to the Handbook of Coronary Stents 16 pgs. (1999).
C18	Mauduit et al., <i>Hydrolytic degradation of films prepared from blends of high and low molecular weight poly(DL-lactic acid)s</i> , J. Biomed. Mater. Res. v. 30, pp. 201-207 (1996).
C19	Martin et al., <i>Enhancing the biological activity of immobilized osteopontin using a type-1 collagen affinity coating</i> , J. Biomed. Mater Res 70A, pp. 10-19 (2004).
C20	Middleton et al., <i>Synthetic biodegradable polymers as orthopedic devices</i> , Biomaterials, vol. 21, pp. 2335-2346 (2000).
C21	Muller et al., <i>Advances in Coronary Angioplasty: Endovascular Stents</i> , Coron. Arter. Dis., 1(4), pp. 438-448 (Jul/Aug. 1990).
C22	Nichols et al., <i>Electrical Insulation of Implantable Devices by Composite Polymer Coatings</i> , ISA Transactions, 26(4), pp.15-18 (1987).
C23	Peuster et al., <i>A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits</i> , Heart 86, pp. 563-569 (2001).
C24	Pietrzak et al., <i>Bioresorbable implants – practical considerations</i> , Bone v. 19, no. 1, Supplement July 1996: 109S-119S.
C25	Pietrzak et al., <i>Bioabsorbable Fixation Devices: Status for the Craniomaxillofacial Surgeon</i> , J. Craniofacial Surg. 2, pp. 92-96 (1997).
C26	von Recum et al., <i>Degradation of polydispersed poly(L-lactic acid) to modulate lactic acid release</i> , Biomaterials 16, pp. 441-445 (1995).
C27	Redman, <i>Clinical Experience with Vasovasostomy Utilizing Absorbable Intravasal Stent</i> , Urology, Vol. 20(1), pp. 59-61 (July 1982).
C28	Rust et al., <i>The Effect of Absorbable Stenting on Postoperative Stenosis of the Surgically Enlarged Maxillary Sinus Ostia in a Rabbit Animal Model</i> , Archives of Otolaryngology, Vol. 122(12) pp. 1395-1397 (December 1996).
C29	Schatz, <i>A View of Vascular Stents</i> , Circulation, 79(2), pp. 445-457 (Feb. 1989).
C30	Schmidt et al., <i>Long-Term Implants of Parylene-C Coated Microelectrodes</i> , Med & Biol Eng & Comp, 26(1), pp. 96-101 (Jan. 1988).
C31	Spagnuolo et al., <i>Gas 1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis</i> , Blood 103, pp. 3005-3012 (2004).
C32	Tamai et al., <i>Initial and 6-Month Results of Biodegradable Poly-L-Lactic Acid Coronary Stents in Humans</i> , Circulation, pp. 399-404 (2000).
C33	Tsui et al., <i>Biodegradable Polymeric Stents</i> , Current Interventional Cardiology Reports 3, pp. 10-17 (2001).
C34	Völkel et al., <i>Targeting of immunoliposomes to endothelial cells using a single –chain Fv fragment directed against human endoglin (CD105)</i> , Biochemica et Biophysica Acta 1663, pp. 158-166 (2004).

	C35	Yau et al. "Modern Size-Exclusion Liquid Chromatography, Wiley-Interscience Publication, (1979).
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		